ES2177923T3 - Procedimiento de separacion de las inmunoglobulinas g y a. - Google Patents

Procedimiento de separacion de las inmunoglobulinas g y a.

Info

Publication number
ES2177923T3
ES2177923T3 ES97900978T ES97900978T ES2177923T3 ES 2177923 T3 ES2177923 T3 ES 2177923T3 ES 97900978 T ES97900978 T ES 97900978T ES 97900978 T ES97900978 T ES 97900978T ES 2177923 T3 ES2177923 T3 ES 2177923T3
Authority
ES
Spain
Prior art keywords
igg
iga
optionally
immunoglobulins
separation procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97900978T
Other languages
English (en)
Inventor
Heinz Leibl
Regine Tomasits
Josef Mannhalter
Hermann Wolf
Martha Eibl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter AG filed Critical Baxter AG
Application granted granted Critical
Publication of ES2177923T3 publication Critical patent/ES2177923T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE DESCRIBE UN PROCEDIMIENTO PARA SEPARAR IGC E IGA DE UN MATERIAL DE PARTIDA CON CONTENIDO DE INMUNOGLOBULINA. ESTE PROCEDIMIENTO SE CARACTERIZA PORQUE (I) IGC Y, OPCIONALMENTE, IGA SON ABSORBIDOS EN UN MATERIAL PORTANTE INORGANICO SOLIDO, PORQUE (II) IGA ES OBTENIDO DEL ELUATO, OPCIONALMENTE TRAS SU DESORCION SELECTIVA, PERMANECIENDO MIENTRAS TANTO EL IGC EN EL MATERIAL PORTANTE Y, OPCIONALMENTE, PORQUE (III) EL IGC ES OBTENIDO DEL ADSORBATO. ADEMAS, SE DA A CONOCER UN PREPARADO IGA QUE MUESTRA UNA MENOR TENDENCIA A FORMAR AGREGADOS.
ES97900978T 1996-01-12 1997-01-09 Procedimiento de separacion de las inmunoglobulinas g y a. Expired - Lifetime ES2177923T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19600939A DE19600939C1 (de) 1996-01-12 1996-01-12 Verfahren zur Trennung von IgG und IgA

Publications (1)

Publication Number Publication Date
ES2177923T3 true ES2177923T3 (es) 2002-12-16

Family

ID=7782616

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97900978T Expired - Lifetime ES2177923T3 (es) 1996-01-12 1997-01-09 Procedimiento de separacion de las inmunoglobulinas g y a.

Country Status (11)

Country Link
US (1) US6646108B1 (es)
EP (1) EP0873362B1 (es)
JP (1) JP2000503644A (es)
AT (1) ATE219104T1 (es)
AU (1) AU727797B2 (es)
BR (1) BR9707140A (es)
CA (1) CA2242778A1 (es)
DE (2) DE19600939C1 (es)
DK (1) DK0873362T3 (es)
ES (1) ES2177923T3 (es)
WO (1) WO1997025352A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP806999A0 (en) * 1999-01-08 1999-02-04 Csl Limited Process for purifying immunoglobulins
KR100703340B1 (ko) * 2004-12-11 2007-04-03 삼성전자주식회사 인터넷 프로토콜 기반의 디지털 방송 시스템에서 방송채널 정보를 제공하기 위한 장치 및 방법
TW200821026A (en) * 2006-09-08 2008-05-16 Wyeth Corp Arginine wash in protein purification using affinity chromatography
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
CN104254542A (zh) 2012-03-09 2014-12-31 瑞士杰特贝林生物制品有限公司 包含分泌-样免疫球蛋白的组合物
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2404265C3 (de) * 1974-01-30 1980-05-29 Behringwerke Ag, 3550 Marburg Verfahren zum Abreichen von Immunglobulinen
JPS5759815A (en) 1980-09-30 1982-04-10 Mochida Pharmaceut Co Ltd Drug composition having preventing and remedying action on rotavirus infectious disease
DE3173208D1 (en) 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
AT383737B (de) 1983-03-16 1987-08-10 Immuno Ag Verfahren zur verwendung einer immunoglobulin-g enthaltenden fraktion
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4745183A (en) * 1984-02-21 1988-05-17 Bio-Rad Laboratories, Inc. Use of hydroxylapatite for the analysis and preparation of purified monoclonal antibodies
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
JPH0669961B2 (ja) 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPH0762674B2 (ja) 1986-03-07 1995-07-05 株式会社高研 クロマトグラフイ−用吸着剤、及びその製造方法、並びに該吸着剤を使用したクロマトグラフイ−カラム
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JPH03291300A (ja) * 1989-12-28 1991-12-20 Mitsui Toatsu Chem Inc ポリクローナル抗体の分離方法
AT402789B (de) 1991-03-25 1997-08-25 Immuno Ag Pharmazeutische präparation auf basis von plasmaproteinen
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
DE4434538C2 (de) 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens
JPH09509164A (ja) * 1994-02-18 1997-09-16 イムノ・アクテイエンゲゼルシヤフト 免疫グロブリンａを用いた炎症を予防及び治療するための組成物並びに方法
DE4424935C1 (de) * 1994-07-14 1996-03-21 Immuno Ag Humanes virussicheres monomeres Immunglobulin A und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
AU1440197A (en) 1997-08-01
CA2242778A1 (en) 1997-07-17
EP0873362A1 (de) 1998-10-28
BR9707140A (pt) 1999-05-18
DE19600939C1 (de) 1997-08-28
EP0873362B1 (de) 2002-06-12
JP2000503644A (ja) 2000-03-28
ATE219104T1 (de) 2002-06-15
DE59707496D1 (de) 2002-07-18
DK0873362T3 (da) 2002-08-26
US6646108B1 (en) 2003-11-11
WO1997025352A1 (de) 1997-07-17
AU727797B2 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
AU4936593A (en) Method and device for separating gas components by adsorption
ZA836645B (en) Control system and method for air fractionation by vacuum swing adsorption
ZA963967B (en) Device and process for separating gases by adsorption
DE69120951D1 (de) Verfahren zur adsorption schwefelhaltiger bestandteile aus propylen/propan-gas unter verwendung von regenerierbaren adsorbenzien
TR199600608A2 (tr) Azotun diger gazlardan adsorpsiyonla ayrilmasi.
AU7256987A (en) Method of affinity purification employing monoclonal antibodies
PL374311A1 (en) Methods for purifying protein
LTC0868125I2 (lt) Adsorbentas fosfato adsorbavimui iš vandeninės terpės, to adsorbento gavimas ir panaudojimas
NL193831B (nl) Werkwijze voor de bereiding van zwaardere koolwaterstoffen uit lichte, gasvormige koolwaterstoffen.
EP0972530A4 (en) ADSORBENT FOR ELIMINATION OF HEPATITIS C VIRUS, ADSORBER AND METHOD OF ADSORPTION
AU4485493A (en) Method for generating monoclonal antibodies from rabbits
NL193108B (nl) Werkwijze voor het zuiveren van een anthracyclinon-glycoside.
FI972233A0 (fi) Menetelmä kaasumaisten saastuttavien aineiden erottamiseksi kuumista prosessikaasuista
AU6507399A (en) Method for selective adsorption of dienes
MY127954A (en) A method of chromatographic isolation for non-glyceride components
AU4234389A (en) Method for the reduction of heterogeneity of monoclonal antibodies
AU1578683A (en) Separation of gases by adsorption
DE59707496D1 (de) VERFAHREN ZUR TRENNUNG VON IgG und IgA
DK0923599T3 (da) Fremgangsmåde til fremstilling af 17-estere af 9alfa, 21-dihalogenpregnan-11beta, 17alfa-diol-20-oner
WO2001017537A3 (en) Methods and compositions for reducing immune response
EP0674936A3 (en) Method of using silica-amino functional components for the selective separation of gases.
DE69911754D1 (en) Adsoptionschromatographie
GB2222448B (en) Cut-off valves for pipelines
AU1550783A (en) Method of affinity purification employing monoclonal antibodies
EP0323842A3 (en) Method of purification of transforming growth factor-beta